InvestorsHub Logo
Followers 146
Posts 27517
Boards Moderated 4
Alias Born 02/07/2004

Re: None

Monday, 06/05/2017 8:39:11 AM

Monday, June 05, 2017 8:39:11 AM

Post# of 190
Kamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director

REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (KMDA) (KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the appointment of Michal Stein, M.D., as Vice President and Medical Director for Immunology. Dr. Stein will lead Kamada's medical affairs in all of the Company’s Immunology and specific IgGs products and indications, such as Type-1 Diabetes, Graft vs. Host Disease (GvHD), transplantations and Anti-Rabies IgG, as well as potential new initiatives.

Dr. Stein brings over 15 years of experience in the healthcare industry, including 12 years in increasingly senior positions at multi-national pharmaceutical companies in Israel. Prior to joining Kamada, she served for four years as Medical Director at Sanofi. In this position, Dr. Stein led the medical affairs and pharmacovigilance departments of the Israeli unit of the company, overseeing all aspects of product life-cycle management. From 2009 through 2013, Dr. Stein held multiple positions of increasing responsibility at Merck Sharp & Dohme, including Pharmacovigilance Country Lead, Medical & Scientific Liaisons Team Leader and Medical Affairs Manager, with expertise in vaccines, women’s health and HIV. From 2005 through 2009, she served as Medical Affairs Manager, with expertise in oncology, at Roche Pharmaceuticals. Prior to that, from 2001 through 2005, Dr. Stein was a practicing physician in Israel, first at Rabin Medical Center, Belinson Campus, and then at Schneider Children’s Medical Center.

Dr. Stein holds an M.D. from the Tel-Aviv Sackler Faculty of Medicine.

“We are pleased to welcome Dr. Stein to the Kamada executive team,” said Amir London, Chief Executive Officer of Kamada. “Dr. Stein has significant medical affairs and pharmaceutical operations expertise. Her vast talents and industry experience will be of significant value to us as we continue to drive growth in our commercial product portfolio, and further develop our robust late-stage pipeline across multiple indications.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KMDA News